Multiple lines of evidence support the hypothesis that over-activation of FGF19/FGFR4 pathway, as well as FGF19, FGFR4 and KLB gene amplifications, may promote HCC growth, malignant progression, metastasis and drug resistance [73–76]. The gene discussed is KLB; the disease is hepatocellular carcinoma.